These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25160805)

  • 41. Efficiency of follicle-stimulating hormone, commenced in the luteal phase, for overcoming a poor response in assisted reproduction.
    Kucuk T; Göktolga U; Sozen E
    J Obstet Gynaecol Res; 2008 Aug; 34(4):574-7. PubMed ID: 18946938
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Luteal-phase ovarian stimulation is a feasible method for poor ovarian responders undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer treatment compared to a GnRH antagonist protocol: A retrospective study.
    Wei LH; Ma WH; Tang N; Wei JH
    Taiwan J Obstet Gynecol; 2016 Feb; 55(1):50-4. PubMed ID: 26927248
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Can the fall in serum FSH during coasting in IVF/ICSI predict clinical outcomes?
    Datta AK; Zosmer A; Tozer A; Sabatini L; Davis C; Al-Shawaf T
    Reprod Biomed Online; 2012 May; 24(5):503-10. PubMed ID: 22417663
    [TBL] [Abstract][Full Text] [Related]  

  • 44. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study.
    Pirard C; Donnez J; Loumaye E
    Hum Reprod; 2006 Jul; 21(7):1894-900. PubMed ID: 16556673
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study.
    Isik AZ; Caglar GS; Sozen E; Akarsu C; Tuncay G; Ozbicer T; Vicdan K
    Reprod Biomed Online; 2009 Oct; 19(4):472-7. PubMed ID: 19909586
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of GnRH agonist and antagonist protocols in normoresponder patients who had IVF-ICSI.
    Kara M; Aydin T; Aran T; Turktekin N; Ozdemir B
    Arch Gynecol Obstet; 2013 Dec; 288(6):1413-6. PubMed ID: 23708392
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist.
    Lu X; Hong Q; Sun L; Chen Q; Fu Y; Ai A; Lyu Q; Kuang Y
    Fertil Steril; 2016 Nov; 106(6):1356-1362. PubMed ID: 27490046
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Arabian Peninsula ethnicity is associated with lower ovarian reserve and ovarian response in women undergoing fresh ICSI cycles.
    Tabbalat AM; Pereira N; Klauck D; Melhem C; Elias RT; Rosenwaks Z
    J Assist Reprod Genet; 2018 Feb; 35(2):331-337. PubMed ID: 29063502
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels.
    Feldberg D; Farhi J; Ashkenazi J; Dicker D; Shalev J; Ben-Rafael Z
    Fertil Steril; 1994 Aug; 62(2):343-6. PubMed ID: 8034083
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Route of progesterone administration for luteal phase support may affect outcome of controlled ovarian hyperstimulation for IVF with ICSI using GnRH antagonist.
    Bahceci M; Ulug U
    J Assist Reprod Genet; 2008; 25(9-10):499-502. PubMed ID: 18941886
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
    Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; van Wely M
    Cochrane Database Syst Rev; 2010 Nov; (11):CD008046. PubMed ID: 21069701
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols.
    Toftager M; Bogstad J; Løssl K; Prætorius L; Zedeler A; Bryndorf T; Nilas L; Pinborg A
    Hum Reprod; 2017 Mar; 32(3):556-567. PubMed ID: 28130435
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET.
    Tsakos E; Tolikas A; Daniilidis A; Asimakopoulos B
    Arch Gynecol Obstet; 2014 Dec; 290(6):1249-53. PubMed ID: 25001569
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparing stimulation requirements and final outcome between early follicular and mid luteal pituitary suppression in the long gonadotropin releasing hormone agonist protocol.
    Sarhan A; Harira M; Elshazly S; Nouh A
    JBRA Assist Reprod; 2016 May; 20(2):59-61. PubMed ID: 27244762
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of r-FSH alone and in combination with r-LH.
    Levi-Setti PE; Cavagna M; Bulletti C
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):212-6. PubMed ID: 16377062
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Luteal support for IVF/ICSI cycles with Crinone 8% (90 mg) twice daily results in higher pregnancy rates than with intramuscular progesterone.
    Ho CH; Chen SU; Peng FS; Chang CY; Yang YS
    J Chin Med Assoc; 2008 Aug; 71(8):386-91. PubMed ID: 18772117
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of daily GnRH agonist for luteal phase support following GnRH agonist triggered ICSI cycles versus conventional strategy: A Randomized controlled trial.
    Salehpour S; Nazari L; Hosseini S; Azizi E; Borumandnia N; Hashemi T
    JBRA Assist Reprod; 2021 Jul; 25(3):368-372. PubMed ID: 33507722
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gonadotropin-releasing hormone analogue as sole luteal support in antagonist-based assisted reproductive technology cycles.
    Bar Hava I; Blueshtein M; Ganer Herman H; Omer Y; Ben David G
    Fertil Steril; 2017 Jan; 107(1):130-135.e1. PubMed ID: 28228316
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects and safety of GnRH-a as a luteal support in women undertaking assisted reproductive technology procedures: follow-up results for pregnancy, delivery, and neonates.
    Zhou W; Zhuang Y; Pan Y; Xia F
    Arch Gynecol Obstet; 2017 May; 295(5):1269-1275. PubMed ID: 28357558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.